RT Journal Article
SR Electronic
T1 Thoughts on COVID-19 and autoimmune diseases
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP e000396
DO 10.1136/lupus-2020-000396
VO 7
IS 1
A1 Anca D Askanase
A1 Leila Khalili
A1 Jill P Buyon
YR 2020
UL http://lupus.bmj.com/content/7/1/e000396.abstract
AB Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.